Patient enrollment is complete in a Phase 2b/3 clinical trial evaluating MN-166 (ibudilast), an investigational oral therapy developed by Medicinova to treat amyotrophic lateral sclerosis (ALS). The COMBAT-ALS (NCT04057898) trial is testing whether MN-166 can safely slow ALS progression in 234 adults with ALS, ages 18 to…

Coya Therapeutics has launched a Phase 2 clinical trial of COYA 302 — an experimental therapy combining the signaling molecule IL-2 with CTLA4-Ig, also known as abatacept — to evaluate whether its use can slow disease progression in adults with amyotrophic lateral sclerosis (ALS) over a six-month period.

In adults with amyotrophic lateral sclerosis (ALS) who have slower disease progression, the stem cell therapy Neuronata-R (lenzumestrocel) — conditionally approved in South Korea for treating ALS — was found to help preserve daily function and breathing capacity, while also reducing signs of nerve damage and inflammation. That’s according to…

The UCLA ALS Clinic and Research Center has been officially designated a Certified Treatment Center of Excellence for people in the U.S. with amyotrophic lateral sclerosis (ALS) — making it the 100th center nationwide to receive such recognition. This designation, awarded by the ALS Association, means the…

Nonprofit I AM ALS has teamed up with actor Eric Dane to launch Push for Progress, a three-year campaign focused on accelerating research on amyotrophic lateral sclerosis (ALS), expanding access to treatments, and securing $1 billion in federal funding. Dane, best known for his roles in “Grey’s…

Ionis Pharmaceuticals recently celebrated the 10th anniversary of its Surf Away+ program, a day of adaptive sports and beach fun that has welcomed people with amyotrophic lateral sclerosis (ALS) alongside those with other neurological diseases. Held Sept. 12 at the beach in Oceanside, California, the event brought together…

In a new initiative, Mosaic Neuroscience is teaming up with Ixcells Biotechnologies to develop patient-specific cell models that could lay the foundation for advancing precision medicine in amyotrophic lateral sclerosis (ALS). The pilot project is the first to be launched as part of Project Mosaic, an effort —…

Long-read DNA sequencing is a more accurate method than short-read sequencing for detecting certain defects in genes associated with an increased risk of sporadic amyotrophic lateral sclerosis (ALS), a new study suggests. A relatively new technique, long-read sequencing can capture data on thousands to hundreds of thousands of nucleotides,…

The investigational antisense oligonucleotide (ASO) therapy BIIB078 may have failed in amyotrophic lateral sclerosis (ALS) clinical trials because it wasn’t adequately reversing key disease processes in the brain and spinal cord. Analyses of body fluids and tissue from participants showed that, while BIIB078 reached key tissues, it couldn’t entirely…

AP-101, AL-S Pharma’s amyotrophic lateral sclerosis (ALS) therapy, was safe and well tolerated and led to clinically meaningful benefits for breathing and survival after one year of treatment. That’s according to topline data from a now-complete Phase 2a study (NCT05039099) that tested the therapy in 73 adults with…